{"text": "There was no difference between patient groups with regard to sex, age, type of prosthesis and time since operation, though anticoagulant status was more often inadequate in group II.", "user_data": {"pmid": "10224577"}}
{"text": "By TEE, valve motion was normal in all patients.", "user_data": {"pmid": "10224577"}}
{"text": "In one patient, seven days' of unsuccessful heparin was followed by two months' successful coumarin therapy.", "user_data": {"pmid": "10224577"}}
{"text": "There were no critical changes in heart rate or blood pressure in either group.", "user_data": {"pmid": "10414756"}}
{"text": "The EF showed no significant changes in the two groups.", "user_data": {"pmid": "10661479"}}
{"text": "MWC showed a slight, insignificant decrease in both groups.", "user_data": {"pmid": "10661479"}}
{"text": "From ECG no significant ST deviations were found and no significant changes regarding B-Hb, blood pressure or pulse were observed in the two groups.", "user_data": {"pmid": "10661479"}}
{"text": "Irregular heart rhythm aggravated in one patient during the first month of treatment with rhGH, but was overcome by a -blocking agent.", "user_data": {"pmid": "10661479"}}
{"text": "Systemic thrombolytic therapy significantly reduced the number of closed vein segments after 12 months in patients with acute DVT compared with conventional treatment (p < 0.05).", "user_data": {"pmid": "11028492"}}
{"text": "Postthrombotic syndrome also occurred with less frequency in systemically treated patients versus controls (p < 0.001).", "user_data": {"pmid": "11028492"}}
{"text": "High-dose thrombolysis led to better rates of complete recanalization after seven days (p < 0.01) than locoregional lysis.", "user_data": {"pmid": "11028492"}}
{"text": "The cardiovascular death in the therapy group was due to stroke.", "user_data": {"pmid": "11302295"}}
{"text": "Controlling for depression, previous myocardial infarction, low ejection fraction, decreased heart rate variability, and ventricular ectopic beats had little impact on estimated treatment effect.", "user_data": {"pmid": "11302295"}}
{"text": "Patients undergoing carotid endarterectomy were randomized in a double-blind manner between L-arginine (n=14), GSNO (n=14), or placebo (n=14) administered intravenously for 90 minutes, starting 30 minutes after skin closure.", "user_data": {"pmid": "11352886"}}
{"text": "All patients were pretreated with aspirin and given heparin during surgery.", "user_data": {"pmid": "11352886"}}
{"text": "Transcranial Doppler recordings were made from the ipsilateral middle cerebral artery for 4 hours after surgery, beginning 30 minutes after skin closure, and also at 6 and 24 hours.", "user_data": {"pmid": "11352886"}}
{"text": "There were highly significant reductions in the number of Doppler embolic signals in the L-arginine and GSNO groups; first 4 hours, median (range) number of embolic signals, placebo 44.7 (6 to 778), L-arginine 9.5 (0 to 225), and GSNO 0.8 (0 to 8), both P<0.001 versus control values.", "user_data": {"pmid": "11352886"}}
{"text": "The reduction in the signals persisted at the 24-hour recording.", "user_data": {"pmid": "11352886"}}
{"text": "The free radicals in arterial samples were, respectively, 21, 14, 10 and 9% at 10 min, 1, 2 and 24 h after reperfusion.", "user_data": {"pmid": "11420161"}}
{"text": "Cardiac index (CI) and right ventricular ejection fraction (RVEF) were improved by ischaemic preconditioning.", "user_data": {"pmid": "11420161"}}
{"text": "A total of 142 patients with symptomatic heart failure (New York Heart Association class III and IV) were randomized to double-blind, short-term treatment with conivaptan, a dual V(1a)/V(2) vasopressin receptor antagonist, at a single intravenous dose (10, 20, or 40 mg) or placebo.", "user_data": {"pmid": "11705818"}}
{"text": "Compared with placebo, conivaptan at 20 and 40 mg significantly reduced pulmonary capillary wedge pressure (-2.6+/-0.7, -5.4+/-0.7, and -4.6+/-0.7 mm Hg for placebo and 20 and 40 mg groups, respectively; P<0.05) and right atrial pressure (-2.0+/-0.4, -3.7+/-0.4, and -3.5+/-0.4 mm Hg for placebo and 20 and 40 mg groups, respectively; P<0.05) during the 3- to 6-hour interval after intravenous administration.", "user_data": {"pmid": "11705818"}}
{"text": "Conivaptan significantly increased urine output in a dose-dependent manner (-11+/-17, 68+/-17, 152+/-19, and 176+/-18 mL/hour for placebo and 10, 20, and 40 mg groups, respectively; P<0.001) during the first 4 hours after the dose.", "user_data": {"pmid": "11705818"}}
{"text": "Changes in cardiac index, systemic and pulmonary vascular resistance, blood pressure, and heart rate did not significantly differ from placebo.", "user_data": {"pmid": "11705818"}}
{"text": "Registration included hemodynamic data from the peripheral artery and the pulmonary artery, and the measurement of cardiac troponin I (CTnI) and creatine kinase isoenzyme MB (CK-MB) values.", "user_data": {"pmid": "11948051"}}
{"text": "IP resulted in a complete recovery of the mean stroke volume index (SVI) after the operation.", "user_data": {"pmid": "11948051"}}
{"text": "In the control subjects, the mean SVI showed a significant reduction postoperatively (p = 0.039).", "user_data": {"pmid": "11948051"}}
{"text": "On the first postoperative day, the increase in the mean heart rate (HR) was also significantly lower in the IP patients.", "user_data": {"pmid": "11948051"}}
{"text": "The CTnI level was statistically significantly lower in the IP group (p = 0.043), and IP patients tended to have a smaller CK-MB release after surgery (not significant).", "user_data": {"pmid": "11948051"}}
{"text": "The duration of mechanical ventilation, the length of stay in the ICU, and the use of inotropic medication did not increase after the IP protocol.", "user_data": {"pmid": "11948051"}}
{"text": "No significant difference between the two groups (with respect to the proportions of patients with favourable outcome) was detected in either the analysis of the BI or the NIHSS.", "user_data": {"pmid": "12021946"}}
{"text": "Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range.", "user_data": {"pmid": "12021946"}}
{"text": "Net +/- SEM sponge weight (total intraoperative suture line bleeding) was 6.25 +/- 0.55 g in the BP group and 16.34 +/- 1.85 g in the Dacron group (P<.001).", "user_data": {"pmid": "12093332"}}
{"text": "Total suture line bleeding was significantly affected by activated clotting time; however, multivariate analysis demonstrated that bleeding was significantly less with BP (P<.001) even after adjusting for differences in activated clotting time.", "user_data": {"pmid": "12093332"}}
{"text": "Basal echocardiographic and hemodynamic data were similar in both groups.", "user_data": {"pmid": "12486433"}}
{"text": "After a follow-up period of approximately 4 months, both groups had similar event rates and comparable hemodynamic parameters (P = not significant).", "user_data": {"pmid": "12486433"}}
{"text": "When extrapolated up to 3 years, the gain in life expectancy was estimated at 0.35 years (discounted at 3%).", "user_data": {"pmid": "12559222"}}
{"text": "The incremental cost per life-year saved (LYS) was 3205 at the European level; in the individual countries the cost per LYS ranged between 3091 and 3331.", "user_data": {"pmid": "12559222"}}
{"text": "The result was robust in the sensitivity analysis.", "user_data": {"pmid": "12559222"}}
{"text": "This technique interrupted 3 to 14 (mean, 7) incompetent perforating veins per patient.", "user_data": {"pmid": "12618690"}}
{"text": "In 92% ulcers healed or were significantly improved within 4 to 14 weeks.", "user_data": {"pmid": "12618690"}}
{"text": "Thirty-two patients (4%) experienced recurrent ulceration or skin deterioration at 6 months-2 years (mean, 15 mo).", "user_data": {"pmid": "12618690"}}
{"text": "In the 92 randomized patients with C4 disease, 41 refused postoperative AVP, leaving 51 compliant patients.", "user_data": {"pmid": "12618690"}}
{"text": "The SEPS group (n = 25) had significantly reduced AVP (P <.01) compared with the control group (n = 26).", "user_data": {"pmid": "12618690"}}
{"text": "Complications in 825 patients were less than 3% and consisted mostly of transient neurologic disorders (eg, paradysthesia), but deep venous thrombosis occurred in 2 patients, with pulmonary embolus in 1.", "user_data": {"pmid": "12618690"}}
{"text": "No operative deaths occurred.", "user_data": {"pmid": "12618690"}}
{"text": "Follow-up for 1 to 9 years (mean, 31/2 years) demonstrated durability.", "user_data": {"pmid": "12618690"}}
{"text": "The corresponding numbers in patients with echogenic plaques were n = 4/13 (31%) and n = 4/17 (24%), respectively (NS).", "user_data": {"pmid": "12653872"}}
{"text": "Baseline clinical characteristics and infarct location were well balanced in both groups.", "user_data": {"pmid": "14661011"}}
{"text": "Median age (interquartile range) was 68 (58, 75) years, 29% were women, and 78% of the patients met at least one criterion for \"not low risk\" AMI (anterior location, age >70 years old, previous MI, systolic blood pressure <100 mm Hg, and/or heart rate >100 bpm).", "user_data": {"pmid": "14661011"}}
{"text": "Patients had lower peak oxygen consumption and a steeper slope relating ventilation to carbon dioxide production than controls.", "user_data": {"pmid": "15101027"}}
{"text": "There was no effect on the peak oxygen consumption, exercise time, ventilation to carbon dioxide slope, or anaerobic threshold.", "user_data": {"pmid": "15101027"}}
{"text": "There was an increase in peak tidal volume (VT) in both groups but this did not lead to an increase in peak ventilation.", "user_data": {"pmid": "15101027"}}
{"text": "The slope relating symptoms to ventilation (ie, Borg/VE) was significantly reduced in the patients after bronchodilators (17%+/-8%, P<.05).", "user_data": {"pmid": "15101027"}}
{"text": "The relationship between the improvement in VT and reduction in gradient of the Borg/VE slope was significant (r=.40, P<.05).", "user_data": {"pmid": "15101027"}}
{"text": "Patients with kidney disease were older, more often had CHF as the cause of acute dyspnea, and more often died in-hospital or within 30 days as compared to patients without kidney disease.", "user_data": {"pmid": "15610252"}}
{"text": "In contrast, in patients with kidney disease, time to discharge and total cost of treatment were similar in both groups.", "user_data": {"pmid": "15610252"}}
{"text": "It did not affect the gain of shivering (control, 437 [289] ml min(-1) degrees C(-1); magnesium, 573 [370] ml min(-1) degrees C(-1); P=0.344).", "user_data": {"pmid": "15749735"}}
{"text": "The magnesium bolus did not produce significant sedation or appreciably reduce muscle strength.", "user_data": {"pmid": "15749735"}}
{"text": "After 569 patients had undergone randomization, enrollment was stopped because of concerns about the safety of the patients who had been assigned to receive warfarin.", "user_data": {"pmid": "15800226"}}
{"text": "Patients with severe LV dysfunction on two dimensional echocardiography and low fractional shortening also had significantly higher vWf concentrations than those with no LV dysfunction.", "user_data": {"pmid": "15894770"}}
{"text": "CHF patients with clinical features--with (156 (28) IU/dl) and without (152 (31) IU/dl) LV dysfunction--also had higher mean vWf concentrations than patients with asymptomatic LV dysfunction (146 (31) IU/dl, p < 0.001).", "user_data": {"pmid": "15894770"}}
{"text": "The presence of mitral regurgitation in CHF was associated with lower vWf concentrations.", "user_data": {"pmid": "15894770"}}
{"text": "Plasma sP-sel concentrations were not affected by presence, onset, or severity of heart failure.", "user_data": {"pmid": "15894770"}}
{"text": "Intravenous diltiazem was effective on the improvement of symptom and electrocardiogram, and its effects were similar to intravenous nitroglycerin. (", "user_data": {"pmid": "15929820"}}
{"text": "Compared with nitroglycerin, intravenous diltiazem lowered heart rate and myocardial oxygen consumption index (systolic pressure x heart rate) to more extent significantly. (", "user_data": {"pmid": "15929820"}}
{"text": "After treatment, the onsets of refractory angina pectoris were reduced more significantly in the diltiazem group than in nitroglycerin group [4 (3.8%) vs 13 (11.9%), RR 0.32 (95% CI 0.11 - 0.96), P < 0.05]. (", "user_data": {"pmid": "15929820"}}
{"text": "But these patients could tolerate the lower heart rate very well in the diltiazem group. (", "user_data": {"pmid": "15929820"}}
{"text": "The mean follow-up period was 2.21 years +/- 0.26 (1.89-3.07).", "user_data": {"pmid": "15973098"}}
{"text": "Nine patients (7%) could not be monitored at 1 or 2 years, but 4 of these 9 nevertheless filled in the 1-year questionnaire.", "user_data": {"pmid": "15973098"}}
{"text": "The patients in the SH group experienced less postoperative pain/discomfort as scored by pain during bowel movement (P < 0.001), total analgesic requirement over the first 3 days (according to the World Health Organization [WHO] class II analgesics [P = 0.002]; class III [P = 0.066]), and per-patient consumption frequency of class III analgesics (P = 0.089).", "user_data": {"pmid": "15973098"}}
{"text": "A clear difference in morphine requirement became evident after 24 hours (P = 0.010).", "user_data": {"pmid": "15973098"}}
{"text": "At 1 year, no differences in the resolution of symptoms were observed between the 2 groups, and over 2 years, the overall incidence of complications was the same, specifically fecaloma (P = 0.003) in the MM group and external hemorrhoidal thrombosis (P = 0.006) in the SH group.", "user_data": {"pmid": "15973098"}}
{"text": "Impaired sphincter function was observed at 1 year with no significant difference between the groups for urgency (12%), continence problems (10%), or tenesmus (3%).", "user_data": {"pmid": "15973098"}}
{"text": "No patient needed a second procedure for recurrence within 2 years, although partial residual prolapse was detected in 4 SH patients (7.5%) versus 1 MM patient (1.8%) (P = 0.194).", "user_data": {"pmid": "15973098"}}
{"text": "Both treatments were well tolerated.", "user_data": {"pmid": "16038713"}}
{"text": "A total of 308 patients (91.9%) completed the study and 145 cases (47.1%) received angiographic follow-up.", "user_data": {"pmid": "16454975"}}
{"text": "The incidence of recurrent angina at 3 and 6 months after PCI was also significantly reduced in XS0601 group (7.1% and 11.0%) as compared with those in placebo group (19.5% and 42.9%) (P < 0.05).", "user_data": {"pmid": "16454975"}}
{"text": "No significant side effects occurred within the 6-month follow-up period in the XS0601 group.", "user_data": {"pmid": "16454975"}}
{"text": "During follow-up, HBI had no impact on all-cause mortality (relative risk, 1.04; 95% confidence interval, 0.80-1.35) or event-free survival from death or unplanned hospitalization (relative risk, 1.03; 95% confidence interval, 0.86-1.24).", "user_data": {"pmid": "16567604"}}
{"text": "Initial analysis suggested that HBI had only a marginal impact in reducing unplanned hospitalization, with 677 readmissions vs 824 for the usual care group (mean +/- SD rate, 0.72 +/- 0.96 vs 0.84 +/- 1.20 readmissions/patient per year; P = .08).", "user_data": {"pmid": "16567604"}}
{"text": "When accounting for increased hospital activity in HBI patients with chronic obstructive pulmonary disease during follow-up for 2 years, post hoc analyses showed that HBI reduced readmissions by 14% within 2 years in patients without this condition (mean +/- SD rate, 0.54 +/- 0.72 vs 0.63 +/- 0.88 readmission/patient per year; P = .04) and by 21% in all surviving patients within 3 to 8 years (mean +/- SD rate, 0.64 +/- 1.26 vs 0.81 +/- 1.61 readmissions/patient per year; P = .03).", "user_data": {"pmid": "16567604"}}
{"text": "Overall, recurrent hospital costs were significantly lower (14%) in the HBI group (mean +/- SD, 823 dollars +/- 1642 dollars vs 960 dollars +/- 1376 dollars per patient per year; P = .045).", "user_data": {"pmid": "16567604"}}
{"text": "No patients had sustained postbaseline ventricular tachycardia events, postbaseline run of ventricular ectopic beats associated with relevant symptoms (e.g. hypotension, syncope), or an episode of ventricular flutter or fibrillation.", "user_data": {"pmid": "16911869"}}
{"text": "Vital signs and electrocardiogram data, including corrected QT intervals (Bazett and Fridericia), were similar across treatment groups.", "user_data": {"pmid": "16911869"}}
{"text": "The most common adverse events, infections and respiratory events, were expected for this patient population.", "user_data": {"pmid": "16911869"}}
{"text": "The incidence of cardiac adverse events was low (1 formoterol and 4 placebo patients).", "user_data": {"pmid": "16911869"}}
{"text": "Both groups had patients with severe postoperative pain (3 each) and fecal incontinence (1 patient each).", "user_data": {"pmid": "16957977"}}
{"text": "The overall difference in the number of complications in the two groups was statistically significant (p < 0.05).", "user_data": {"pmid": "16957977"}}
{"text": "Six dogs with microembolizations-induced HF and 9 HF patients underwent CCM leads and generator (OPTIMIZER II) implantation.", "user_data": {"pmid": "17395055"}}
{"text": "After baseline measurements, CCM signals were delivered continuously for 2 hours in dogs and for 30 minutes in patients.", "user_data": {"pmid": "17395055"}}
{"text": "MVO(2) was measured before and after CCM therapy.", "user_data": {"pmid": "17395055"}}
{"text": "As with dogs, the increase in LV function after 30 minutes of CCM therapy was not associated with increased MVO(2) (13.6 +/- 9.7 versus 12.5 +/- 7.2 mL O(2)/min).", "user_data": {"pmid": "17395055"}}
{"text": "Regarding safety, 35 dogs in each group experienced at least one adverse event.", "user_data": {"pmid": "17472664"}}
{"text": "Nine dogs in each group experienced at least one serious adverse event.", "user_data": {"pmid": "17472664"}}
{"text": "The difference between these results was not statistically significant.", "user_data": {"pmid": "17472664"}}
{"text": "Of the 1309 patients randomized, 842 (64.3%) were evaluable for efficacy.", "user_data": {"pmid": "17723125"}}
{"text": "Statin withdrawal was associated with a 4.66 (1.46 to 14.91)-fold increase in the risk of death or dependency, a 8.67 (3.05 to 24.63)-fold increase in the risk of END, and an increase in mean infarct volume of 37.63 mL (SE 10.01; p < 0.001) after adjusting for age and baseline stroke severity.", "user_data": {"pmid": "17724294"}}
{"text": "Compared with patients without previous treatment with statins, statin withdrawal was associated with a 19.01 (1.96 to 184.09)-fold increase in the risk of END and an increase in mean infarct volume of 43.51 mL (SE 21.91; p = 0.048).", "user_data": {"pmid": "17724294"}}
{"text": "From 15% to 40% of these events occurred beyond 30 days.", "user_data": {"pmid": "17880325"}}
{"text": "At 6 months, 3%, 4%, and 13% of patients died in low-, medium-, and high-risk groups, respectively.", "user_data": {"pmid": "17880325"}}
{"text": "However, the proportion of patients dying beyond 30 days was similar in the three groups (44%, 43%, and 41% of death, respectively).", "user_data": {"pmid": "17880325"}}
{"text": "Similarly, whereas death or MI increased with higher risk (11%, 14%, and 23%, respectively), the proportion of patients with this event beyond 30 days did not differ in the three strata (22%, 20%, and 25%, respectively).", "user_data": {"pmid": "17880325"}}
{"text": "The rates of adverse clinical events in the groups were low and equal.", "user_data": {"pmid": "19833610"}}
{"text": "There were no significant differences between groups in change of global LV systolic function by echocardiography or magnetic resonance imaging (MRI) during the follow-up.", "user_data": {"pmid": "19833610"}}
{"text": "Although there were significant variations across sites in the management of post-CABG AF, patterns of use of postoperative rhythm versus rate control and anticoagulation did not differ by geographic region or by whether or not the enrolling site was an academic institution.", "user_data": {"pmid": "19853700"}}
{"text": "Mortality was higher in patients with post-CABG AF than patients without AF at 30 days (1.5% vs 0.7%, P = .01) but not at 3 years (6.9% vs 4.9%, P = .41).", "user_data": {"pmid": "19853700"}}
{"text": "There was a trend toward a higher risk of mortality or stroke at 30 days in patients with AF (2.4% vs 1.9%, P = .08).", "user_data": {"pmid": "19853700"}}
{"text": "In the cangrelor group, as compared with the placebo group, two prespecified secondary end points were significantly reduced at 48 hours: the rate of stent thrombosis, from 0.6% to 0.2% (odds ratio, 0.31; 95% CI, 0.11 to 0.85; P=0.02), and the rate of death from any cause, from 0.7% to 0.2% (odds ratio, 0.33; 95% CI, 0.13 to 0.83; P=0.02).", "user_data": {"pmid": "19915222"}}
{"text": "Among the 227 randomized subjects, 33 (14.5%) had SBI at baseline.", "user_data": {"pmid": "20431290"}}
{"text": "The new brain infarcts of subjects in the active group were subclinical.", "user_data": {"pmid": "20431290"}}
{"text": "Among the placebo group, the new brain infarcts of 3 subjects were symptomatic while those of the remaining 5 subjects were subclinical.", "user_data": {"pmid": "20431290"}}
{"text": "Among putative variables, multivariate regression analysis showed that only the baseline number of SBIs (OR = 6.27, 95% CI 2.4-16.5) and simvastatin treatment (OR = 0.09, 95% CI 0.01-0.82) independently predicted the development of new brain infarcts.", "user_data": {"pmid": "20431290"}}
{"text": "Baseline characteristics were similar between the two groups.", "user_data": {"pmid": "20815045"}}
{"text": "Multivariate logistic analysis showed that insulin treatment was the only independent predictor of MACE [odds ratio (OR) 8.60, 95% confidence interval (CI) 3.25-22.76, P < 0.001] and target vessel revascularization (TVR) (OR 9.50, 95% CI 3.07-29.44, P < 0.001) during the three-year follow-up.", "user_data": {"pmid": "20815045"}}
{"text": "There were no statistically significant differences between the two groups at baseline.", "user_data": {"pmid": "20865676"}}
{"text": "After the intervention, the MAT/TT index of all patients normalized in each evaluation period with statistically significant differences.", "user_data": {"pmid": "20865676"}}
{"text": "One hundred twenty-four patients were recruited over a 23-month period.", "user_data": {"pmid": "21048092"}}
{"text": "There was no significant reduction in morbidity on any measured postoperative day.", "user_data": {"pmid": "21048092"}}
{"text": "Complication rates, mortality, and hospital length of stay were similar between the 2 groups; however, administration of dopexamine was associated with earlier return of tolerating an enteral diet.", "user_data": {"pmid": "21048092"}}
{"text": "LV lead implantation was successful in all patients.", "user_data": {"pmid": "21276573"}}
{"text": "No major complications occurred.", "user_data": {"pmid": "21276573"}}
{"text": "There were 67 patients in each group.", "user_data": {"pmid": "8391792"}}
{"text": "Venographic assessment of clot size evolution between day 0 and day 10 showed a statistically significant superiority (P < .002) of enoxaparin over the reference treatment with UFH.", "user_data": {"pmid": "8391792"}}
{"text": "There were no serious bleeding complications in either group.", "user_data": {"pmid": "8391792"}}
{"text": "Among the 417 patients with adequate venograms, 109 of 211 warfarin recipients (51.7%) had deep venous thrombosis compared with 76 of 206 enoxaparin recipients (36.9%) (P = 0.003).", "user_data": {"pmid": "8607589"}}
{"text": "The absolute risk difference was 14.8% in favor of enoxaparin (95% Cl, 5.3% to 24.1%) Twenty-two warfarin recipients (10.4%) and 24 enoxaparin recipients (11.7%) had proximal venous thrombosis (P>0.2).", "user_data": {"pmid": "8607589"}}
{"text": "The absolute risk difference was 1.2% in favor of warfarin (Cl, -7.2% to 4.8%).", "user_data": {"pmid": "8607589"}}
{"text": "The absolute risk difference was 0.3% in favor of warfarin (Cl, -2.4% to 1.8%).", "user_data": {"pmid": "8607589"}}
{"text": "One scan was indeterminate and a follow-up venogram was negative.", "user_data": {"pmid": "8779018"}}
{"text": "At base line, the transfusion group had a slightly lower mean hemoglobin concentration (7.2 vs. 7.6 g per deciliter, P=0.001) and hematocrit (20.4 vs. 21.7 percent, P=0.002).", "user_data": {"pmid": "9647873"}}
{"text": "This result led to the early termination of the trial.", "user_data": {"pmid": "9647873"}}
{"text": "In segments with diagnostic MCE, the segmental sensitivity ranged from 14% to 65%, and the specificity varied from 78% to 95%, depending on the dose of contrast agent.", "user_data": {"pmid": "9809934"}}
{"text": "Using both segment- and patient-based analysis, the greatest accuracy and proportion of interpretable images were obtained using harmonic imaging in the triggered mode.", "user_data": {"pmid": "9809934"}}
{"text": "For the detection of extensive defects, the sensitivity varied from 13% to 48%, with specificity from 63% to 100%.", "user_data": {"pmid": "9809934"}}
{"text": "Harmonic imaging remained the most accurate approach.", "user_data": {"pmid": "9809934"}}
{"text": "Time since MI and SPECT defect location and intensity were all determinants of the MCE response.", "user_data": {"pmid": "9809934"}}
{"text": "The extent of defects on MCE was less than the extent of either abnormal wall motion or SPECT abnormalities.", "user_data": {"pmid": "9809934"}}
